Grants |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Government Assistance [Abstract] | |
| Grants | 11. Grants
The Company recorded grant revenue of $0 during the three and six months ended June 30, 2026, and $57,480 and $336,108 during the three and six months ended June 30, 2025, respectively, in connection with a $2,500,000 grant from the State of Tennessee (the “Tennessee Grant”). The Tennessee Grant was provided as reimbursement of research and development expenses related to the development of animal health drug products. All grant revenue related to the Tennessee Grant was recognized as of June 30, 2025. No additional revenue will be recognized for expenses incurred in connection with the Tennessee Grant. As of June 30, 2026 and December 31, 2025, the Company did not have any unearned grant revenue liability on the accompanying condensed consolidated balance sheet.
|